Discouraging news for high-dose chemotherapy in high-risk breast cancer

Ovarian reserve as a measure of adjuvant chemotherapy benefit in hormone receptor positive (HR-positive), HER2-negative, node-positive breast cancer in SWOG S1007 (RxPONDER).

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival.

ESMO open·2025

A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2024

Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis.

Annals of oncology : official journal of the European Society for Medical Oncology·2021

Immunological differences between primary and metastatic breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2018

A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).

Annals of oncology : official journal of the European Society for Medical Oncology·2018

Conversational diagnostic artificial intelligence in ambulatory primary care: a prospective feasibility study.

Lancet (London, England)·2026

Oral deucrictibant for on-demand treatment of hereditary angioedema attacks: a phase 3, multicentre, randomised, double-blind, placebo-controlled crossover trial.

Lancet (London, England)·2026

Migraine.

Lancet (London, England)·2026

The public health challenges of children's and adolescents' digital media use: applying the digital determinants of health as an interpretive framework.

Lancet (London, England)·2026

Governing the digital determinants of health for children and young people: a global public health imperative.

Lancet (London, England)·2026

From Phase Ib/II to Seamless Phase II/III: A Simulation-Based Discussion of Design Strategies for Dose Optimization and Confirmatory Phase.

Clinical pharmacology and therapeutics·2026

INSR Armoring Protects CAR-NK and CAR-T Cells Against Tumor Stroma-Induced CAR Shedding by Maintaining Cholesterol Homeostasis.

Cancer research·2026

Matching-adjusted indirect treatment comparisons in chronic inflammatory demyelinating polyneuropathy: interpreting current evidence and enhancing future studies.

Journal of comparative effectiveness research·2026

Epidemiology of medication-related problems and antimicrobial utilisation among critically ill cancer patients: Determinants, pharmacist interventions and clinical outcomes-A prospective observational study.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners·2026

Enhancing Cancer Immunotherapy with Berberine and Its Loaded Nanoparticles: A Systematic Review.

Anti-cancer agents in medicinal chemistry·2026

Magnetic and Non-Magnetic Halloysite Nanotubes Functionalized with Folic Acid for the Targeted Delivery of [Pd(dipic)Cl].H2O: Cytotoxicity and Apoptosis Induction in Colon Cancer Cells.

Anti-cancer agents in medicinal chemistry·2026

Related Experiment Videos

Discouraging news for high-dose chemotherapy in high-risk breast cancer

Related Concept Videos

Ovarian reserve as a measure of adjuvant chemotherapy benefit in hormone receptor positive (HR-positive), HER2-negative, node-positive breast cancer in SWOG S1007 (RxPONDER).

Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival.

A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial.

Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis.

Immunological differences between primary and metastatic breast cancer.

A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).

Conversational diagnostic artificial intelligence in ambulatory primary care: a prospective feasibility study.

Oral deucrictibant for on-demand treatment of hereditary angioedema attacks: a phase 3, multicentre, randomised, double-blind, placebo-controlled crossover trial.

Migraine.

The public health challenges of children's and adolescents' digital media use: applying the digital determinants of health as an interpretive framework.

Governing the digital determinants of health for children and young people: a global public health imperative.

From Phase Ib/II to Seamless Phase II/III: A Simulation-Based Discussion of Design Strategies for Dose Optimization and Confirmatory Phase.

INSR Armoring Protects CAR-NK and CAR-T Cells Against Tumor Stroma-Induced CAR Shedding by Maintaining Cholesterol Homeostasis.

Matching-adjusted indirect treatment comparisons in chronic inflammatory demyelinating polyneuropathy: interpreting current evidence and enhancing future studies.

Epidemiology of medication-related problems and antimicrobial utilisation among critically ill cancer patients: Determinants, pharmacist interventions and clinical outcomes-A prospective observational study.

Enhancing Cancer Immunotherapy with Berberine and Its Loaded Nanoparticles: A Systematic Review.

Magnetic and Non-Magnetic Halloysite Nanotubes Functionalized with Folic Acid for the Targeted Delivery of [Pd(dipic)Cl].H2O: Cytotoxicity and Apoptosis Induction in Colon Cancer Cells.

Related Experiment Videos

Discouraging news for high-dose chemotherapy in high-risk breast cancer

Related Concept Videos

Related Articles